These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38807146)

  • 1. Safety, tolerability, pharmacokinetics, and pharmacodynamics of TG103 injection in participants who are overweight or obese: a randomized, double-blind, placebo-controlled, multiple-dose phase 1b study.
    Lin D; Xiao H; Yang K; Li J; Ye S; Liu Y; Jing S; Lin Y; Yang Y; Huang L; Yuan J; Li Z; Yang J; Gao H; Xie Y; Xu M; Yan L
    BMC Med; 2024 May; 22(1):209. PubMed ID: 38807146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.
    Enebo LB; Berthelsen KK; Kankam M; Lund MT; Rubino DM; Satylganova A; Lau DCW
    Lancet; 2021 May; 397(10286):1736-1748. PubMed ID: 33894838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, pharmacokinetics, and pharmacodynamics of TG103, a novel long-acting GLP-1/Fc fusion protein after a single ascending dose in Chinese healthy subjects.
    Jin J; Cui G; Mi N; Wu W; Zhang X; Xiao C; Wang J; Qiu X; Han M; Li Z; Wang L; Lu T; Niu H; Wu Z; Li J
    Eur J Pharm Sci; 2023 Jun; 185():106448. PubMed ID: 37062422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
    Ambery P; Parker VE; Stumvoll M; Posch MG; Heise T; Plum-Moerschel L; Tsai LF; Robertson D; Jain M; Petrone M; Rondinone C; Hirshberg B; Jermutus L
    Lancet; 2018 Jun; 391(10140):2607-2618. PubMed ID: 29945727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.
    Urva S; Coskun T; Loh MT; Du Y; Thomas MK; Gurbuz S; Haupt A; Benson CT; Hernandez-Illas M; D'Alessio DA; Milicevic Z
    Lancet; 2022 Nov; 400(10366):1869-1881. PubMed ID: 36354040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
    O'Neil PM; Birkenfeld AL; McGowan B; Mosenzon O; Pedersen SD; Wharton S; Carson CG; Jepsen CH; Kabisch M; Wilding JPH
    Lancet; 2018 Aug; 392(10148):637-649. PubMed ID: 30122305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.
    Kadowaki T; Isendahl J; Khalid U; Lee SY; Nishida T; Ogawa W; Tobe K; Yamauchi T; Lim S;
    Lancet Diabetes Endocrinol; 2022 Mar; 10(3):193-206. PubMed ID: 35131037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
    Lau DCW; Erichsen L; Francisco AM; Satylganova A; le Roux CW; McGowan B; Pedersen SD; Pietiläinen KH; Rubino D; Batterham RL
    Lancet; 2021 Dec; 398(10317):2160-2172. PubMed ID: 34798060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
    Rubino D; Abrahamsson N; Davies M; Hesse D; Greenway FL; Jensen C; Lingvay I; Mosenzon O; Rosenstock J; Rubio MA; Rudofsky G; Tadayon S; Wadden TA; Dicker D;
    JAMA; 2021 Apr; 325(14):1414-1425. PubMed ID: 33755728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial.
    Ji L; Gao L; Jiang H; Yang J; Yu L; Wen J; Cai C; Deng H; Feng L; Song B; Ma Q; Qian L
    EClinicalMedicine; 2022 Dec; 54():101691. PubMed ID: 36247927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised, phase 1, dose-finding study of MEDI4166, a PCSK9 antibody and GLP-1 analogue fusion molecule, in overweight or obese patients with type 2 diabetes mellitus.
    Jain M; Carlson G; Cook W; Morrow L; Petrone M; White NE; Wang T; Naylor J; Ambery P; Lee C; Hirshberg B
    Diabetologia; 2019 Mar; 62(3):373-386. PubMed ID: 30593607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
    Rubino DM; Greenway FL; Khalid U; O'Neil PM; Rosenstock J; Sørrig R; Wadden TA; Wizert A; Garvey WT;
    JAMA; 2022 Jan; 327(2):138-150. PubMed ID: 35015037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
    Rosenstock J; Frias J; Jastreboff AM; Du Y; Lou J; Gurbuz S; Thomas MK; Hartman ML; Haupt A; Milicevic Z; Coskun T
    Lancet; 2023 Aug; 402(10401):529-544. PubMed ID: 37385280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.
    Wadden TA; Bailey TS; Billings LK; Davies M; Frias JP; Koroleva A; Lingvay I; O'Neil PM; Rubino DM; Skovgaard D; Wallenstein SOR; Garvey WT;
    JAMA; 2021 Apr; 325(14):1403-1413. PubMed ID: 33625476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
    Loomba R; Morgan E; Watts L; Xia S; Hannan LA; Geary RS; Baker BF; Bhanot S
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):829-838. PubMed ID: 32553151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study.
    Loomba R; Lawitz EJ; Frias JP; Ortiz-Lasanta G; Johansson L; Franey BB; Morrow L; Rosenstock M; Hartsfield CL; Chen CY; Tseng L; Charlton RW; Mansbach H; Margalit M
    Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):120-132. PubMed ID: 36521501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial.
    Zhao L; Cheng Z; Lu Y; Liu M; Chen H; Zhang M; Wang R; Yuan Y; Li X
    JAMA; 2024 Aug; 332(7):551-560. PubMed ID: 38819983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
    Davies M; Færch L; Jeppesen OK; Pakseresht A; Pedersen SD; Perreault L; Rosenstock J; Shimomura I; Viljoen A; Wadden TA; Lingvay I;
    Lancet; 2021 Mar; 397(10278):971-984. PubMed ID: 33667417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
    Garvey WT; Frias JP; Jastreboff AM; le Roux CW; Sattar N; Aizenberg D; Mao H; Zhang S; Ahmad NN; Bunck MC; Benabbad I; Zhang XM;
    Lancet; 2023 Aug; 402(10402):613-626. PubMed ID: 37385275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.